

(54) Title of the invention : DUAL ANTIBODY CONJUGATED LIPIDIC NANOPARTICLES OF DAPT TO TARGET TRIPLE NEGATIVE BREAST CANCER CELLS

(51) International classification	:C07K0016220000, A61K0009510000, A61K0039395000, A61K0039000000, A61K0009127000	(71)Name of Applicant : 1)JSS College of Pharmacy, Ooty - JSS Academy of Higher Education & Research, Mysuru Address of Applicant :Rocklands, Post Box No.: 20, Ooty, The Nilgiris, Tamil Nadu-643 001, India. Tamil Nadu India
(31) Priority Document No	:NA	(72)Name of Inventor :
(32) Priority Date	:NA	1)KRISHNAMURTHY, Praveen Thaggikuppe
(33) Name of priority country	:NA	2)KUMARI, Mamta
(86) International Application No	:PCT//	3)ACHARYA, Amitabha
Filing Date	:01/01/1900	4)DAR, Aqib Iqbal
(87) International Publication No	: NA	5)CHINTAMANENI, Pavan kumar
(61) Patent of Addition to Application Number:	NA	6)Piyongsola
Filing Date	:NA	7)AMMU, Veera. Venkata. Vajra. Ravi Kiran
(62) Divisional to Application Number	:NA	8)GARIKAPATI, Kusuma Kumari
Filing Date	:NA	9)PINDIPROLU, Satya Sesha Sai kiran

(57) Abstract :

Dual antibody conjugated lipidic nanoparticles of DAPT to target triple negative breast cancer cells. The present invention discloses N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine-butylester (DAPT) encapsulated solid lipid nanoparticles surface modified with DLL4 and DR5 anti-bodies, to target cell-specific binding of Triple Negative Breast Cancer. More particularly, the present invention discloses Dual antibody conjugated lipidic nanoparticles of DAPT (DLL4-DR5-DAPT@SLNs), to target TNBC cell-specific binding and thereby inhibiting the notch signaling.

No. of Pages : 44 No. of Claims : 5